Arvinas, Inc. announced positive pharmacokinetic, pharmacodynamic, and biomarker data from two Phase 1 clinical trials evaluating ARV-102, an oral, brain-penetrant investigational PROTAC degrader of leucine-rich repeat kinase 2 (LRRK2). The results were presented at the International Congress of Parkinson’s Disease and Movement Disorders (MDS 2025).
ARV-102 was well tolerated in both healthy volunteers and patients with Parkinson’s disease, demonstrating dose-dependent cerebrospinal fluid (CSF) exposure in both trials. Notably, after 14 days of treatment in healthy volunteers, ARV-102 decreased lysosomal and neuroinflammatory microglial pathway biomarkers known to be elevated in Parkinson’s disease.
This marks the first time an investigational LRRK2 therapy has shown effects on distal pathway biomarkers in CSF in healthy volunteers within 14 days. These findings support the intensified development of ARV-102 in ongoing studies of patients with Parkinson’s disease and in future studies for progressive supranuclear palsy.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.